Agata Hanna Bryk1,2, Małgorzata Konieczyńska2, Maciej Polak3, Dariusz Plicner4, Maciej Bochenek5, Anetta Undas6,7. 1. Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland. 2. John Paul II Hospital, Krakow, Poland. 3. Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland. 4. Unit of Experimental Cardiology and Cardiac Surgery, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland. 5. Clinic of Cardiac Transplantation and Mechanical Circulatory Support, Department of Heart Diseases, Wroclaw Medical University, Wrocław, Poland. 6. John Paul II Hospital, Krakow, Poland. mmundas@cyf-kr.edu.pl. 7. Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202, Krakow, Poland. mmundas@cyf-kr.edu.pl.
Abstract
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are at high risk of cardiovascular mortality, but the mechanisms behind this remain unclear. Prothrombotic fibrin clot properties have been shown in T2DM and cardiovascular disease. We hypothesized that formation of denser clots, which are resistant to fibrinolysis, has a negative impact on cardiovascular mortality in T2DM. METHODS: We studied 133 T2DM patients aged 43-83 years. Plasma fibrin clot turbidity, permeation, compaction, and efficiency of clot lysis using 3 assays including the determination of maximum concentration (D-Dmax) and rate of increase in D-dimer concentration (D-Drate) released during tissue plasminogen activator-induced degradation, were evaluated at the time of enrollment, along with thrombin generation and fibrinolytic proteins. During a median follow-up period of 72 months, cardiovascular mortality was recorded. RESULTS: Cardiovascular deaths (n = 16, 12%) occurred more frequently in patients with increased D-Dmax (> 4.26 mg/l, hazard ratio [HR] 5.43, 95% confidence interval [CI] 1.99-14.79), or decreased D-Drate (< 0.07 mg/l/min, HR 2.97, 95% CI 1.07-8.23), or increased peak thrombin (> 283.5 nM, HR 5.65, 95% CI 2.07-15.51). These predictors had an even more potent impact on cardiovascular mortality in patients with prior cardiovascular disease (64.7%) and with corresponding risks as follows: HR 6.18, 95% CI 2.02-18.96; HR 8.98, 95% CI 2.99-26.96; and HR 5.35, 95% CI 1.62-17.72, respectively. Other investigated fibrin variables and fibrinolytic proteins did not associate with cardiovascular mortality. In multivariable analysis, cardiovascular mortality was predicted by D-Dmax > 4.26 mg/l, age > 65 years, prior cardiovascular disease, and C-reactive protein > 3 mg/l. CONCLUSIONS: This study is the first to show that formation of denser fibrin clots resistant to fibrinolysis could be a risk factor for long-term cardiovascular mortality in T2DM.
BACKGROUND:Patients with type 2 diabetes mellitus (T2DM) are at high risk of cardiovascular mortality, but the mechanisms behind this remain unclear. Prothrombotic fibrin clot properties have been shown in T2DM and cardiovascular disease. We hypothesized that formation of denser clots, which are resistant to fibrinolysis, has a negative impact on cardiovascular mortality in T2DM. METHODS: We studied 133 T2DM patients aged 43-83 years. Plasma fibrin clot turbidity, permeation, compaction, and efficiency of clot lysis using 3 assays including the determination of maximum concentration (D-Dmax) and rate of increase in D-dimer concentration (D-Drate) released during tissue plasminogen activator-induced degradation, were evaluated at the time of enrollment, along with thrombin generation and fibrinolytic proteins. During a median follow-up period of 72 months, cardiovascular mortality was recorded. RESULTS:Cardiovascular deaths (n = 16, 12%) occurred more frequently in patients with increased D-Dmax (> 4.26 mg/l, hazard ratio [HR] 5.43, 95% confidence interval [CI] 1.99-14.79), or decreased D-Drate (< 0.07 mg/l/min, HR 2.97, 95% CI 1.07-8.23), or increased peak thrombin (> 283.5 nM, HR 5.65, 95% CI 2.07-15.51). These predictors had an even more potent impact on cardiovascular mortality in patients with prior cardiovascular disease (64.7%) and with corresponding risks as follows: HR 6.18, 95% CI 2.02-18.96; HR 8.98, 95% CI 2.99-26.96; and HR 5.35, 95% CI 1.62-17.72, respectively. Other investigated fibrin variables and fibrinolytic proteins did not associate with cardiovascular mortality. In multivariable analysis, cardiovascular mortality was predicted by D-Dmax > 4.26 mg/l, age > 65 years, prior cardiovascular disease, and C-reactive protein > 3 mg/l. CONCLUSIONS: This study is the first to show that formation of denser fibrin clots resistant to fibrinolysis could be a risk factor for long-term cardiovascular mortality in T2DM.
Entities:
Keywords:
Cardiovascular mortality; D-dimer; Fibrin clot; Type 2 diabetes
Authors: J P Colle; Z Mishal; C Lesty; M Mirshahi; J Peyne; A Baumelou; A Bensman; J Soria; C Soria Journal: Thromb Haemost Date: 1999-11 Impact factor: 5.249
Authors: Agnieszka Okraska-Bylica; Tadeusz Wilkosz; Lidia Słowik; Marta Bazanek; Małgorzata Konieczyńska; Anetta Undas Journal: Pol Arch Med Wewn Date: 2012-12-11
Authors: R L R Carter; K Talbot; W S Hur; S C Meixner; J G Van Der Gugten; D T Holmes; H C F Côté; C J Kastrup; T W Smith; A Y Y Lee; E L G Pryzdial Journal: J Thromb Haemost Date: 2018-10-09 Impact factor: 5.824
Authors: Ramshanker Ramanathan; Jørgen B Gram; Johannes J Sidelmann; Damini Dey; Martin W Kusk; Bjarne L Nørgaard; Niels Peter R Sand Journal: Thromb Res Date: 2018-12-19 Impact factor: 3.944
Authors: Deepak L Bhatt; John W Eikelboom; Stuart J Connolly; P Gabriel Steg; Sonia S Anand; Subodh Verma; Kelley R H Branch; Jeffrey Probstfield; Jackie Bosch; Olga Shestakovska; Michael Szarek; Aldo Pietro Maggioni; Petr Widimský; Alvaro Avezum; Rafael Diaz; Basil S Lewis; Scott D Berkowitz; Keith A A Fox; Lars Ryden; Salim Yusuf Journal: Circulation Date: 2020-03-28 Impact factor: 29.690
Authors: Irina N Chernysh; Chandrasekaran Nagaswami; Sofia Kosolapova; Alina D Peshkova; Adam Cuker; Douglas B Cines; Carolyn L Cambor; Rustem I Litvinov; John W Weisel Journal: Sci Rep Date: 2020-03-20 Impact factor: 4.379
Authors: Pauline C S van Paridon; Marina Panova-Noeva; Rene van Oerle; Andreas Schultz; Iris M Hermanns; Jürgen H Prochaska; Nathalie Arnold; Harald Binder; Irene Schmidtmann; Manfred E Beutel; Norbert Pfeiffer; Thomas Münzel; Karl J Lackner; Hugo Ten Cate; Philipp S Wild; Henri M H Spronk Journal: Haematologica Date: 2020-09-01 Impact factor: 9.941